While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer's disease, drugmaker Novo Nordisk announced on Nov. 24.

Pharmaceutical giant Novo Nordisk says an oral version of semaglutide — the active ingredient in blockbuster drugs Ozempic ...

Health officials have repeatedly warned Britons against buying the jabs on social media and to be aware of scam online ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.

Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

Novo Nordisk had hoped to repurpose semaglutide - the active ingredient in its Wegovy and Ozempic jabs - as a groundbreaking ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.